




Lab Ref. No : SDA230057991	Centre : DR DANGS LAB
Name : MASTER. ARYAN	Client : CAN KIDS
Age / Gender : 5 Y 0 M 0 D /MALE	Collection Time : 10-08-2023 05:48 PM
Ref. By Dr : SELF	Reporting Time : 11-08-2023 05:27 PM
	Report Status : Final Report

DEPARTMENT OF HAEMATOLOGY**MINIMAL RESIDUAL DISEASE (MRD)****Flow ID:** 2308F149M101**Clinical History:** Case of B-ALL/HR. End of induction MRD under evaluation.**Specimen:** Bone marrow in EDTA and Heparin.**TLC in flow-cytometry bone marrow specimen** –23,810/ul.**CD markers used:** Surface: CD45, CD19, CD10, CD34, CD38, CD58, CD73, CD86, CD20, CD123, CD81 and Syto13**Descriptive summary:**

8-colour, 3-laserflowcytometry done on a BD FACS CANTO™ II flow cytometer. Analysis was done on FACS Diva™ v8.0.3 software.

Gating Strategy: The tubes were run till empty/ acquisition of a minimum 2.0 million events. In each tube, 2 million events could be acquired. Exclusion of doublets on FSC-A vs FSC-H plot followed by exclusion of debris on the FSC vs SSC was done. Populations were gated on CD45 vs CD19 plot. Cells with abnormal expression of surface markers (expression pattern different from normal 'B' precursors and LAIPs) were looked for. The final MRD population is calculated with respect to nucleated cell population obtained from Syto13 tube.**Total CD19 positive events:** 2720.The bone marrow immune-phenotyping shows a populations of **leukemic blasts constituting ~0.17% of all cells and show dim CD45, moderate CD19, CD86, CD123, CD10, moderate to bright CD73 and negative CD38, CD58 with loss of CD81.****Impression-** The flow-cytometric immune-phenotyping analysis of bone marrow specimen in a case of B-ALL shows **presence of Leukemic Blasts (~0.17%). Minimal residual disease is positive (≥0.01%).**

Please correlate with clinical and therapeutic profile.

***** End Of Report *******DR. SHIKHA GARG**
M.D.(PATHOLOGY)**DR. MANAVI DANG**
M.D. (PATHOLOGY)

ALL

Aryan

Fever x 12 Days

- Paller's

Initial - TLC \rightarrow 45800.

DLC \rightarrow 488%

PLT \rightarrow 12,000.

L \rightarrow 8 cm.

S \rightarrow 6 cm.

BMA - NO (434/23)

- 94% Blast

Flow \rightarrow CALLA Positive B cell ALL.

Cytogenetic \rightarrow Hyperdiploidy XY, +6, +10, +14 +2, +21 |
46,XY[3].

D₈ - Absolute blast. 52% at (in 200 cells). ABC = 1302

D₈ - CSF Cyto \rightarrow TLC - 0 cells.

D₃₅ \rightarrow Bone Marrow. - in Morphological Remission
MRD positive (0.17%)

To repeat BMA + MRD at end of consolidation

\rightarrow Neg (at the end of consolidation)

DEPARTMENT OF PATHOLOGY

LADY HARDINGE MEDICAL COLLEGE & SMT. S.K. HOSPITAL, NEW DELHI

CYTOLOGY REPORT FORM

Name of Patient..... Axon..... Sex S/X Age M Regd. No. 30218

Hospital LHMC Ward 1/2 CS Dr. In-Charge

Case No 622/23 Smear No 1497-98/23

Received on 12/12/23 Reported on 12/12/23

Investigation asked for :-

CSF for Malignant cytology (F-1497-98/23)

Cross: Received 0.5 ml of clear colorless fluid

TLC - 05 cells /cmm

DLC - 19 Mononuclear, 01 Polymorphs (out of 20 cells)

Report :-

Microscopy: Leptosin preparation shows many lymphocytes

and occasional macrophage

No atypical cell / blast cell seen on the preparation examined

Lab Ref. No : SDA230057991
 Name : MASTER, ARYAN
 Age / Gender : 5 Y 0 M 0 D / MALE
 Ref. By Dr : SELF

Centre : DR DANGS LAB
 Client : CAN KIDS
 Collection Time : 10-08-2023 05:48 PM
 Reporting Time : 11-08-2023 05:27 PM
 Report Status : Final Report

DEPARTMENT OF HAEMATOLOGY

MINIMAL RESIDUAL DISEASE (MRD)

Flow ID: 2308F149M101

Clinical History: Case of B-ALL/HR. End of induction MRD under evaluation.

Specimen: Bone marrow in EDTA and Heparin.

TLC in flow-cytometry bone marrow specimen -23,810/ul.

CD markers used: Surface: CD45, CD19, CD10, CD34, CD38, CD58, CD73, CD86, CD20, CD123, CD81 and Syto13

Descriptive summary:

8-colour, 3-laserflowcytometry done on a BD FACS CANTO™ II flow cytometer. Analysis was done on FACS Diva™ v8.0.3 software.

Gating Strategy: The tubes were run till empty/ acquisition of a minimum 2.0 million events. In each tube, 2 million events could be acquired. Exclusion of doublets on FSC-A vs FSC-H plot followed by exclusion of debris on the FSC vs SSC was done. Populations were gated on CD45 vs CD19 plot. Cells with abnormal expression of surface markers (expression pattern different from normal 'B' precursors and LAIPs) were looked for. The final MRD population is calculated with respect to nucleated cell population obtained from Syto13 tube.


Total CD19 positive events: 2720.


The bone marrow immune-phenotyping shows a populations of leukemic blasts constituting ~0.17% of all cells and show dim CD45, moderate CD19, CD86, CD123, CD10, moderate to bright CD73 and negative CD38, CD58 with loss of CD81.

Impression- The flow-cytometric immune-phenotyping analysis of bone marrow specimen in a case of B-ALL shows presence of Leukemic Blasts (~0.17%). Minimal residual disease is positive (≥0.01%).

Please correlate with clinical and therapeutic profile.


*** End Of Report ***


 DR. SHIKHA GARG
 M.D.(PATHOLOGY)


 DR. MANAVI DANG
 M.D. (PATHOLOGY)

Arjan
 sy/M
 B-cell ALL (HR)
 ICICLE ALL-14

BSA = 0.77m²



⁴Mercaptopurine: 60mg/m²/day once at night.

BMA + MRD
 sent on 25/10/23

DRAFT NOT A





JEEVAN CARE FOUNDATION

Address:- 697, Village Madanpur Khadar, New Delhi 110076
Mail- Jeevancarefoundation@gmail.com

Reg No. 92

Ref. No.

Date 14/12/2023

सेवा में

श्रीमान फाउंडर महोदय
जीवन केयर फाउंडेशन,

महोदय

मैं लक्ष्मी का पिता जितन राम आपसे निवेदन करता हूँ कि मेरा लक्ष्मी ब्लड कैंसर से गम्भीर समस्या की उदालत से झुझ रहा हूँ कृपया करके आर्थिक रूप से सहायता प्रदान करें मेरा परिवार और मैं आपके जीवन भर अभारीत रहेंगे।

आर्थी
जितन राम

